Microtubule Targeting Agents in Disease: Classic Drugs, Novel Roles
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Microtubule-targeting agents (MTAs) represent one of the most successful first-line therapies prescribed for cancer treatment. They interfere with microtubule (MT) dynamics by either stabilizing or destabilizing MTs, and in culture, they are believed to kill cells via apoptosis after eliciting mitotic arrest, among other mechanisms. This classical view of MTA therapies persisted for many years. However, the limited success of drugs specifically targeting mitotic proteins, and the slow growing rate of most human tumors forces a reevaluation of the mechanism of action of MTAs. Studies from the last decade suggest that the killing efficiency of MTAs arises from a combination of interphase and mitotic effects. Moreover, MTs have also been implicated in other therapeutically relevant activities, such as decreasing angiogenesis, blocking cell migration, reducing metastasis, and activating innate immunity to promote proinflammatory responses. Two key problems associated with MTA therapy are acquired drug resistance and systemic toxicity. Accordingly, novel and effective MTAs are being designed with an eye toward reducing toxicity without compromising efficacy or promoting resistance. Here, we will review the mechanism of action of MTAs, the signaling pathways they affect, their impact on cancer and other illnesses, and the promising new therapeutic applications of these classic drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Roth, G. A., Abate, D., Abate, K. H., Abay, S. M., Abbafati, C., Abbasi, N., Abbastabar, H., Abd-Allah, F., Abdela, J., Abdelalim, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32203-7 · Cited by 8,600
Targeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717
Dynamic instability of microtubule growth
Mitchison, T., & Kirschner, M. (1984) · Nature · doi:10.1038/312237a0 · Cited by 3,337 · cited 1×
“Periods of growth and shrinking alternate in a cycle known as dynamic instability [5].”
BackgroundHIF-1α pathway: role, regulation and intervention for cancer therapy
Masoud, G. N., & Li, W. (2015) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2015.05.007 · Cited by 1,871
Hirokawa, N., Niwa, S., & Tanaka, Y. (2010) · Neuron · doi:10.1016/j.neuron.2010.09.039 · Cited by 1,138
Structure-based classification of tauopathies
Shi, Y., Zhang, W., Yang, Y., Murzin, A. G., Falcon, B., Kotecha, A., van Beers, M., Tarutani, A., Kametani, F., Garringer, H. J., et al. (2021) · Nature · doi:10.1038/s41586-021-03911-7 · Cited by 878 · cited 1×
“Neurodegenerative disorders affecting Tau proteins are called tauopathies, with Alzheimer’s and Parkinson’s diseases being the most well-known and most studied [63,64].”
BackgroundGascoigne, K. E., & Taylor, S. S. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.07.002 · Cited by 832
The therapeutic journey of benzimidazoles: A review
Bansal, Y., & Silakari, O. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.09.013 · Cited by 817 · cited 1×
“It has been shown that compounds derived from benzimidazole have antitumor activity, antiviral activity, and anti-inflammatory, antihypertensive, and anticoagulant properties [35].”
Backgroundp53 status determines the role of autophagy in pancreatic tumour development
Rosenfeldt, M. T., O’Prey, J., Morton, J. P., Nixon, C., MacKay, G., Mrowinska, A., Au, A., Rai, T. S., Zheng, L., Ridgway, R., et al. (2013) · Nature · doi:10.1038/nature12865 · Cited by 713
Primary Cilia and Mammalian Hedgehog Signaling
Bangs, F., & Anderson, K. V. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028175 · Cited by 642
Siemann, D. W. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.05.001 · Cited by 611
Lacey, E. (1988) · International Journal for Parasitology · doi:10.1016/0020-7519(88)90175-0 · Cited by 560 · cited 1×
“In vitro studies of benzimidazole compounds show that they bind with greater affinity to the β-tubulin site of worms than the equivalent site in humans, effectively blocking MT polymerization at lower drug concentrations in the parasites [36].”
BackgroundAdvances in tau-focused drug discovery for Alzheimer's disease and related tauopathies
Brunden, K. R., Trojanowski, J. Q., & Lee, V. M.-Y. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2959 · Cited by 440
Zhang, B., Maiti, A., Shively, S., Lakhani, F., McDonald-Jones, G., Bruce, J., Lee, E. B., Xie, S. X., Joyce, S., Li, C., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406361102 · Cited by 413
Zhang, B., Carroll, J., Trojanowski, J. Q., Yao, Y., Iba, M., Potuzak, J. S., Hogan, A.-M. L., Xie, S. X., Ballatore, C., Smith, A. B., et al. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.4922-11.2012 · Cited by 401 · cited 1×
“Epothilone D was identified as a brain penetrant MSA, and when used at even lower doses than the ones required for cancer treatment, it was able to improve the axonal MT density and transport, decrease axonal dystrophy, and improve the cognitive deficits in a transgenic Tau mouse model [56,74].”
BackgroundAlbendazole, mebendazole and praziquantel. Review of non-clinical toxicity and pharmacokinetics
Dayan, A. D. (2003) · Acta Tropica · doi:10.1016/s0001-706x(03)00031-7 · Cited by 371
Tubulin-Targeting Chemotherapy Impairs Androgen Receptor Activity in Prostate Cancer
Zhu, M.-L., Horbinski, C. M., Garzotto, M., Qian, D. Z., Beer, T. M., & Kyprianou, N. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0585 · Cited by 352
Dolastatin 10, a powerful cytostatic peptide derived from a marine animal
Bai, R., Petit, G. R., & Hamel, E. (1990) · Biochemical Pharmacology · doi:10.1016/0006-2952(90)90613-p · Cited by 321
Mitosis is not a key target of microtubule agents in patient tumors
Komlodi-Pasztor, E., Sackett, D., Wilkerson, J., & Fojo, T. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.228 · Cited by 314 · cited 1×
“It is possible that MTAs are killing cells in interphase because they interfere with processes like vesicular transport, cell morphology and migration, and/or cell signaling pathways [106].”
BackgroundAlbendazole and Mebendazole as Anti-Parasitic and Anti-Cancer Agents: an Update
Chai, J.-Y., Jung, B.-K., & Hong, S.-J. (2021) · The Korean Journal of Parasitology · doi:10.3347/kjp.2021.59.3.189 · Cited by 286
Komlodi-Pasztor, E., Sackett, D. L., & Fojo, A. T. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0999 · Cited by 227
(2018) · Handbook of Clinical Neurology · doi:10.1016/b978-0-12-802395-2.00025-0 · Cited by 225
Primary cilium-dependent signaling mechanisms
Pala, R., Alomari, N., & Nauli, S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112272 · Cited by 205
Clinical Pharmacokinetics of Anthelmintic Drugs
Edwards, G., & Breckenridge, A. M. (1988) · Clinical Pharmacokinetics · doi:10.2165/00003088-198815020-00001 · Cited by 104
Pawluk, S. A., Roels, C. A., Wilby, K. J., & Ensom, M. H. H. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0243-9 · Cited by 59
Cited by
Dhiman, S., Mannan, A., Taneja, A., Mohan, M., & Singh, T. G. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122537 · Cited by 25
Metadata
- Authors
- Wordeman, L., & Vicente, J. J.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2021-11-12
- Volume
- 13
- Issue
- 22
- Pages
- 5650
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W3214351896
- Cited by
- 167
- References
- 25
- FWCI
- 9.46
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.